HomeCompareCDTX vs PM

CDTX vs PM: Dividend Comparison 2026

CDTX yields 0.90% · PM yields 3.48%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PM wins by $28.6K in total portfolio value
10 years
CDTX
CDTX
● Live price
0.90%
Share price
$221.38
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.0K
Annual income
$95.80
Full CDTX calculator →
PM
Philip Morris International
● Live price
3.48%
Share price
$165.34
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,492.02
Full PM calculator →

Portfolio growth — CDTX vs PM

📍 PM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCDTXPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CDTX + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CDTX pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CDTX
Annual income on $10K today (after 15% tax)
$76.79/yr
After 10yr DRIP, annual income (after tax)
$81.43/yr
PM
Annual income on $10K today (after 15% tax)
$296.12/yr
After 10yr DRIP, annual income (after tax)
$2,118.22/yr
At 15% tax rate, PM beats the other by $2,036.79/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CDTX + PM for your $10,000?

CDTX: 50%PM: 50%
100% PM50/50100% CDTX
Portfolio after 10yr
$35.3K
Annual income
$1,293.91/yr
Blended yield
3.67%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

CDTX
Analyst Ratings
1
Strong
7
Buy
3
Hold
Consensus: Buy
Price Target
$181.50
-18.0% upside vs current
Range: $150.00 — $221.50
Altman Z
32.6
Piotroski
2/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.5% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CDTX buys
0
PM buys
0
No recent congressional trades found for CDTX or PM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCDTXPM
Forward yield0.90%3.48%
Annual dividend / share$2.00$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17.2%
Portfolio after 10y$21.0K$49.6K
Annual income after 10y$95.80$2,492.02
Total dividends collected$933.00$11.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy
Analyst price target$181.50$194.30

Year-by-year: CDTX vs PM ($10,000, DRIP)

YearCDTX PortfolioCDTX Income/yrPM PortfolioPM Income/yrGap
1← crossover$10,790$90.34$11,648$408.29$858.00PM
2$11,637$91.11$13,589$495.90$2.0KPM
3$12,543$91.82$15,877$603.21$3.3KPM
4$13,514$92.50$18,580$734.88$5.1KPM
5$14,553$93.14$21,781$896.75$7.2KPM
6$15,665$93.74$25,578$1,096.12$9.9KPM
7$16,856$94.30$30,092$1,342.17$13.2KPM
8$18,131$94.83$35,470$1,646.46$17.3KPM
9$19,495$95.33$41,892$2,023.58$22.4KPM
10$20,956$95.80$49,578$2,492.02$28.6KPM

CDTX vs PM: Complete Analysis 2026

CDTXStock

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

Full CDTX Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this CDTX vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CDTX vs SCHDCDTX vs JEPICDTX vs OCDTX vs KOCDTX vs MAINCDTX vs MOCDTX vs BTICDTX vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.